The two cohorts served as reciprocal controls since the majority of the cancers present in the BRCA1/2 cohort presumably resulted from the patients' pathogenic BRCA1/2 mutations, while the non-BRCA cohort had either negative tests for BRCA1/2 mutations or cancers not associated with BRCA1/2. This evidence concerns the gene BRCA1 and cancer.